190 related articles for article (PubMed ID: 19793711)
1. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
Esper P
Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
[TBL] [Abstract][Full Text] [Related]
3. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
Agarwala SS
Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
[TBL] [Abstract][Full Text] [Related]
4. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
5. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.
Agarwala SS; Ribas A
J Immunother; 2010; 33(6):557-69. PubMed ID: 20551840
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
7. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
8. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Peggs KS; Quezada SA; Korman AJ; Allison JP
Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4: negative regulator of the immune response and a target for cancer therapy.
Keilholz U
J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542
[TBL] [Abstract][Full Text] [Related]
10. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Fong L; Small EJ
J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
[TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of metastatic melanoma: new immunomodulatory agents.
Sznol M
Semin Oncol; 2012 Apr; 39(2):192-203. PubMed ID: 22484191
[TBL] [Abstract][Full Text] [Related]
12. The role of the CTLA4 blockade in the treatment of malignant melanoma.
Cranmer LD; Hersh E
Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
[TBL] [Abstract][Full Text] [Related]
13. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
Robert C; Ghiringhelli F
Oncologist; 2009 Aug; 14(8):848-61. PubMed ID: 19648604
[TBL] [Abstract][Full Text] [Related]
14. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
[TBL] [Abstract][Full Text] [Related]
16. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
Tarhini AA; Kirkwood JM
Expert Opin Biol Ther; 2008 Oct; 8(10):1583-93. PubMed ID: 18774925
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab for advanced melanoma: a nursing perspective.
Ledezma B
Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
[TBL] [Abstract][Full Text] [Related]
18. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
Camacho LH
Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy and cancer: the role of monoclonal antibodies].
Dumontet C
J Chir (Paris); 1989 Dec; 126(12):682-6. PubMed ID: 2695534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]